Integra Lifesciences Holdings (IART) Other Non-Current Liabilities (2009 - 2026)

Integra Lifesciences Holdings has reported Other Non-Current Liabilities for 18 years, with the latest figure at $194.4 million in Q2 2026.

• Quarterly Other Non-Current Liabilities fell 23.21% year-over-year to $194.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $194.4 million (down 23.21% YoY) and the FY2025 annual result came in at $204.3 million, up 39.69% from the prior year.
• Other Non-Current Liabilities eased to $194.4 million in Q2 2026 per IART's latest filing, from $195.6 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $253.2 million in Q2 2025 and troughed at $32.6 million in Q4 2022.
• A 5-year average of $153.8 million and a median of $154.1 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities plunged 72.89% in 2022, then soared 513.31% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $32.6 million in 2022, then jumped by 513.31% to $199.9 million in 2023, then decreased by 26.86% to $146.2 million in 2024, then jumped by 39.69% to $204.3 million in 2025, then declined by 4.84% to $194.4 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $194.4 million, $195.6 million, and $204.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.